TQA3526 / Sino Biopharm - LARVOL DELTA

Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study. (PubMed, Ann Med) - "The safety profile and PK/PD characteristics of TQA3526 support further evaluation of patients with NASH or PBC. This study was registered at https://www.chictr.org.cn/ under the identifier ChiCTR1800019570."

Journal • P1 data • PK/PD data • Addiction (Opioid and Alcohol) • Dermatology • Hepatology • Immunology • Non-alcoholic Steatohepatitis • Primary Biliary Cholangitis • Pruritus • FGF19

[VIRTUAL] Safety,tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid x receptor(FXR)-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase ? study (EASL-ILC-I 2020) - "TQA3526 was well tolerated at single dose up to 10 mg/d, multiple dose up to 1mg/d, with a linear pharmacokinetic and pharmacodynamics profile among all subjects, which proved efficient since 0.5mg."

Clinical • PK/PD data • Dermatology • Pruritus • FGF19

A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC) (clinicaltrials.gov) - P2a; N=130; Not yet recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P2a trial